FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, particularly to an antibody against PD-L1, and to a pharmaceutical composition containing such antibody. Also disclosed is an artificial genetic DNA encoding such antibody or its light or heavy chain, as well as a vector and a cell containing such DNA. Invention also relates to a method for producing an antibody against PD-L1 which provides cultivation of said host cell.
EFFECT: invention allows effectively preventing and/or treating infection or a malignant growth.
22 cl, 1 tbl, 3 ex, 28 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST PD-L1 | 2017 |
|
RU2744911C2 |
| ANTIBODY AGAINST LAG-3 | 2017 |
|
RU2744866C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| RABIES VIRUS-SPECIFIC HUMAN NEUTRALIZING MONOCLONAL ANTIBODY AND NUCLEIC ACID AND METHODS ASSOCIATED WITH THEREOF | 2001 |
|
RU2272809C2 |
| TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND USE THEREOF | 2016 |
|
RU2730605C2 |
